Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Mapping, sequencing and further decoding of human genome sequence in the last decade have completely revolutionized the drug discovery and development efforts. Out of ~3000 disease genes identified by human genome project, it has been estimated that ~500 are disease genes with druggable domains [1]. Currently marketed drugs only target <50% of these genes. This leaves us with hundreds of well-established but still under-utilized drug targets. It has been estimated that a drug with well-established target has much higher chances (~17%) of reaching preclinical development than a drug with not so established drug target (~3%) [2]. So, target identification and selection based on human genome sequence ensures much higher chances of success for the approval of a drug